
Cancer Treatment,
Starts with Finding the Right Treatment Pathway for You.
From a new cancer diagnosis and postoperative adjuvant therapy to recurrence, metastasis or progression after previous treatment, the medical team integrates imaging, pathology, molecular testing and MDT multidisciplinary review to consider surgery, precision radiotherapy, systemic therapy, interventional treatment and other anticancer approaches, with the goal of developing an individualized treatment pathway.
Understand the Full Picture First,
Then Decide the Next Treatment Step.
Different Stages of Cancer,
Require Different Treatment Priorities.
Even for the same cancer type, treatment goals and priorities may differ at diagnosis, after surgery, at recurrence or after metastasis. Identifying the current stage first helps determine what should be prioritized next.
Newly Diagnosed
Newly Diagnosed CancerWhen cancer is newly diagnosed, the first step is usually not to rush into surgery, chemotherapy or radiotherapy, but to confirm the pathology, stage and extent of disease clearly.
After Surgery
Post-Surgery TreatmentAfter surgery, the next step is to evaluate the pathology, stage and recurrence risk to determine whether additional adjuvant treatment and follow-up monitoring are needed.
Cancer Recurrence
Recurrent CancerRecurrence does not mean there are no treatment options left. The location of recurrence, extent of disease and previous treatments need to be reassessed.
Stage IV / Metastatic
Metastatic CancerAfter cancer has metastasized, treatment usually needs to consider both systemic disease control and management of high-risk local lesions in areas such as the brain, bone, liver or lung.
Send us your pathology, latest CT / MRI / PET, current medications and previous treatment records. The medical team can review the available information and help identify the next priority.
Different Cancer Types,
Require Different Treatment Strategies.
Different cancers vary in pathology, patterns of spread and sensitivity to treatment. Select a cancer type to learn about common diagnostic priorities, treatment approaches and how complex cases may be evaluated.
Lung Cancer
From localized disease to metastases in the brain, bone or other sites, treatment planning should integrate staging and molecular testing.
Breast Cancer
ER, PR and HER2 status, together with recurrence or metastasis, help determine the sequence of systemic and local treatment.
Colorectal Cancer
The primary tumor, liver or lung metastases and molecular features should be assessed before deciding the timing of surgery, systemic therapy and local treatment.
Liver Cancer
Tumor number, location and liver function help determine the role of surgery, intervention, ablation, radiotherapy and systemic treatment.
Stomach Cancer
Treatment planning considers pathology, stage, biomarkers such as HER2, and whether peritoneal or distant metastases are present.
Pancreatic Cancer
Key considerations include resectability, vascular involvement, distant metastasis and how systemic and local treatments may be combined.
Prostate Cancer
PSA, Gleason score, imaging and previous treatment guide decisions on local radiotherapy, systemic therapy and management after recurrence.
Kidney Cancer
After recurrence or metastasis, immunotherapy and targeted therapy are often considered together with local treatment of brain, lung, bone or other lesions.
Nasopharyngeal Cancer
Radiotherapy is often a key treatment modality, with the overall plan guided by stage, lymph-node involvement and distant metastasis.
Cervical Cancer
Stage helps determine the role of external-beam radiotherapy, brachytherapy, systemic treatment and further treatment after recurrence.
Brain Tumor / Brain Metastases
The number, size and location of lesions, previous radiotherapy and neurological symptoms help determine whether surgery or precision radiotherapy is appropriate.
Lymphoma
Pathological subtype, stage and treatment response guide systemic therapy, radiotherapy and subsequent reassessment.
You can still send us your pathology, imaging and previous treatment records. Our international patient team can help organize the information and identify the most appropriate specialty for further consultation.
Cancer Treatment Is Not a Single-Choice Question.
Treatment Should Be Centered Around the Patient, Not a Single Machine.
Different treatments may play different roles at different stages. The medical team considers cancer type, stage, tumor location, previous treatment and the patient’s overall condition to determine which approaches should be combined and in what sequence.
Surgical Oncology
For some resectable tumors, surgery remains an important treatment option. The key is choosing the right timing for surgery.
Precision Radiotherapy
The most appropriate precision radiotherapy approach is selected based on tumor location, size and previous treatment.
Systemic Therapy
When there is systemic risk or metastatic disease, drug therapy plays an important role in controlling disease throughout the body.
Interventional Oncology
Interventional treatment may be considered for local control based on tumor location, blood supply and the patient’s overall condition.
Ablation & Local Therapy
For selected localized or oligometastatic lesions, ablation and other local treatments may be considered to improve local control.
Integrated Cancer Care
Care also addresses treatment tolerance, pain, nutrition, rehabilitation and long-term follow-up throughout the treatment journey.
The medical team integrates pathology, imaging, stage, molecular features and previous treatment to determine the priority between local and systemic treatment.
Do Not Decide the Treatment First.
Decide the Treatment Sequence First.
Even when two patients have the same cancer type and stage, their treatment sequence may still differ. The value of MDT is to understand the full disease picture, risks and treatment goals first, then decide which treatment should come first.
When Decisions Start from One Specialty Alone,
the Focus Can Shift to “What We Can Do.”
A single treatment modality is not necessarily wrong. The problem is that without first understanding the overall disease and treatment priorities, “what can be done” can easily be mistaken for “what should be done first.”
MDT Answers Four Key Questions First,
Then Decides How Treatments Should Be Combined.
Treatment decisions are not based only on “what technologies are available.” Pathology, imaging, previous treatment and current risks are reviewed together.
Cancer Has Metastasized,
the Treatment Goals May Change — but Treatment Options Still Remain.
Metastatic cancer usually requires both systemic disease control and management of high-risk local lesions. The treatment goal may shift from simply “removing one tumor” toward long-term control, risk reduction, symptom relief and preservation of quality of life.
Stage IV Treatment Usually Involves More Than One Approach.
The medical team considers systemic disease control, local risks and treatment response together, then decides how systemic therapy, radiotherapy, surgery, intervention or other local treatments should be combined.
Brain Metastases
The number and location of lesions, symptoms and previous radiotherapy help determine the priority of local treatment.
Lung Metastases
The number and size of lesions and overall disease status help determine whether observation, local treatment or systemic therapy is appropriate.
Liver Metastases
The number and location of lesions and liver function help determine whether radiotherapy, intervention, ablation or other local treatments may be appropriate.
Bone Metastases
Pain, fracture risk and the risk of spinal cord compression directly affect whether local treatment should be prioritized.
In reality, some patients still need local treatment for high-risk lesions, symptomatic disease or tumors affecting organ function.
The correct treatment sequence depends on metastatic sites, disease burden, symptoms and sensitivity to systemic treatment.
The Cancer Has Progressed Despite Treatment,
the Next Step Is Not Simply “Switch to Another Drug.”
Disease progression can mean different things. The previous treatment may have lost effectiveness, only a few lesions may have escaped control, or the tumor’s biological characteristics may have changed. Reassessing the reason for progression is essential before deciding the next treatment pathway.
One Treatment Failing Is Not the Same as “All Treatments Have Failed.”
When imaging shows tumor growth or new lesions, the first question is whether the disease is progressing systemically or only in selected lesions. The treatment logic for these two situations can be completely different.
After Progression, the Medical Team Usually Needs to Revisit Four Questions.
Re-Treatment Usually Begins by Reassessing the Tumor.
Repeat Imaging Assessment
Reassess the extent of disease, sites of progression and whether any high-risk lesions need priority treatment.
Review Pathology & Molecular Information Again
Review previous pathology, IHC and genetic testing, and consider repeat tissue sampling or testing when necessary.
Treat Lesions That Have Escaped Control
If only a limited number of lesions are progressing, precision radiotherapy, surgery, ablation or other local treatments may be considered.
Rebuild the Next Treatment Strategy
Based on the updated disease status, decide whether to continue the current plan, adjust systemic therapy, or recombine local and systemic treatment.
From Your Medical Reports,
to a Clear Treatment Pathway.
For international patients, one of the biggest challenges is not only the treatment itself, but knowing where to begin. The journey connects medical record preparation, medical review, examinations and treatment in Guangzhou, followed by continued care after returning home.
The International Patient Journey Is Organized into Six Stages.
Each stage has a different goal: first organize the information, then clarify the treatment direction, and after arrival, finalize and carry out the plan based on actual examination results.
Cancer Treatment,
Does Not Have One Standard Answer for Everyone.
A meaningful treatment plan needs to consider cancer type, stage, pathology and molecular features, previous treatment, disease response and the patient’s overall condition together, before deciding what should be prioritized now.
Questions Patients and Families Ask Most Often
The answers below are intended to explain general treatment principles. Actual recommendations still require review of the individual pathology, imaging, previous treatment and current physical condition.
If the available medical information is sufficiently complete, the team can often establish an approximately 80% preliminary treatment framework before the patient travels, helping the patient understand the likely examinations, treatment direction and general arrangement in advance.
If the information is incomplete, the imaging is outdated or the disease has changed significantly, the medical team may instead recommend a more comprehensive reassessment after arrival in Guangzhou.
For patients with recurrent, metastatic or more complex disease distribution, doctors may arrange whole-body imaging such as PET/MR according to the clinical situation to further assess lesion location, extent and overall disease status, while reducing the chance that important lesions are missed because of limitations in previous imaging coverage or quality.
Approximately 5–7 days at the shortest: This may be suitable for patients who complete the necessary examinations, doctor / MDT review, treatment planning and the first treatment, then return home to continue follow-up treatment when appropriate.
Approximately 15–45 days for a more complete treatment course: A longer stay may be needed when the patient completes a phase of radiotherapy, systemic therapy, combined treatment, additional examinations or observation of treatment response in Guangzhou.
These are common time ranges, not fixed hospitalization or treatment durations. The actual stay depends on the patient’s condition, examination results, treatment approach and physical recovery after treatment.
Not Sure What the Next Treatment Step Should Be?
Submit your existing pathology, latest CT / MRI / PET, current medications and previous treatment records. The medical team can first understand your current condition, then identify what additional information may be needed and what should be evaluated next.